Sign In
Buy NVUS
$3.52
+0 (+0%)
At Close: Aug 17, 2022
We're A Little Worried About Novus Therapeutics's (NASDAQ:NVUS) Cash Burn Rate
07:17pm, Tuesday, 07'th Apr 2020
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
6 Stocks Moving In Wednesday's After-Hours Session
08:52pm, Wednesday, 25'th Mar 2020
Gainers
Micron (NYSE: MU) shares are trading higher after the company reported better-than-expected Q2 EPS and sales results.
Jazz Pharmaceuticals (NASDAQ: JAZZ) shares are...
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 19.)
Biomerica, Inc. (NASDAQ...
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
12:00am, Thursday, 19'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
Wall Street Analysts Are Bullish on Top Healthcare Picks
11:14am, Wednesday, 18'th Mar 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Novus Therapeutics (NVUS) and CareDx (CDNA) with bullish
Wall Street Analysts Are Bullish on Top Healthcare Picks
11:14am, Wednesday, 18'th Mar 2020
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Novus Therapeutics
Novus Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results
11:30am, Tuesday, 17'th Mar 2020
Novus Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
Novus Therapeutics Completes Enrollment of Phase 2a Trial of OP0201 in Pediatric Patients with Acute Otitis Media
11:30am, Monday, 02'nd Mar 2020
Novus Therapeutics completes enrollment of phase 2a trial in patients with acute otitis media (C-006) and expects to report data by early June 2020.
Novus Therapeutics Provides Update on OP0201
11:30am, Monday, 13'th Jan 2020
Novus Therapeutics' OP0201 Phase 2a study C-006 enrollment to be completed in 1Q 2020 and data expected in 2Q 2020.
Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
10:19pm, Friday, 10'th Jan 2020
Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
Hedge Funds Have Never Been More Bullish On Novus Therapeutics, Inc. (NVUS)
06:51pm, Sunday, 22'nd Dec 2019
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedg
Novus Therapeutics to Participate in Two Investor Conferences
01:30pm, Friday, 29'th Nov 2019
Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the company will
Novus Therapeutics Reports Third Quarter 2019 Financial Results
12:30pm, Wednesday, 13'th Nov 2019
-- Management to participate in two investor conferences in December 2019 --
Novus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion
11:30am, Tuesday, 29'th Oct 2019
Novus Therapeutics, Inc. (NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced that the U.S. Food an
